| 8/28/2019 | IG | Moody’s revises Johnson & Johnson view to negative
|
| 6/7/2018 | SP | New Issue: Citigroup sells $3.47 million contingent coupon autocallables on two stocks
|
| 4/16/2018 | SP | New Issue: JPMorgan sells $1.07 million 8.75% contingent interest autocalls tied to two stocks
|
| 4/4/2018 | SP | JPMorgan eyes contingent interest autocallables linked to two stocks
|
| 3/29/2018 | IG | Fitch affirms Johnson & Johnson
|
| 3/28/2018 | SP | New Issue: Barclays prices $3.53 million trigger autocallable contingent yield notes on Johnson & Johnson
|
| 2/12/2018 | SP | Citigroup to price contingent coupon autocallables on three stocks
|
| 1/24/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Johnson & Johnson
|
| 12/4/2017 | SP | Market Commentary: RBC’s $1.37 million gears tied to basket of 29 stocks aim to reweight the Dow Jones Industrial
|
| 11/30/2017 | SP | New Issue: RBC sells $1.37 million buffer gears tied to basket of 29 stocks
|
| 11/20/2017 | SP | New Issue: HSBC sells $2.33 million autocallable contingent income barrier notes on stocks
|
| 11/13/2017 | SP | HSBC plans contingent income barrier autocallables linked to stocks
|
| 11/9/2017 | IG | New Issue: Johnson & Johnson details $4.5 billion five-tranche issue of notes
|
| 11/8/2017 | EMHYPFPV | Market Commentary: Johnson & Johnson sells $4.5 billion bonds; American Electric, Suncor NiSource, KfW price
|
| 11/8/2017 | IG | Market Commentary: Johnson & Johnson sells $4.5 billion bonds; American Electric, Suncor NiSource, KfW price
|
| 11/8/2017 | IG | New Issue: Johnson & Johnson prices $4.5 billion of notes in five tranches
|
| 11/8/2017 | IG | Fitch rates Johnson & Johnson notes AAA
|
| 11/8/2017 | IG | Moody’s rates Johnson & Johnson notes Aaa
|
| 11/8/2017 | IG | Market Commentary: Morning Commentary: Johnson & Johnson, AvalonBay, Mosaic, NiSource, Suncor offer notes
|
| 11/8/2017 | IG | Johnson & Johnson intends to price fixed-rate notes in five parts
|
| 3/23/2017 | SP | TD Bank amends Cusip for Raymond James Quality Yield Equity notes
|
| 3/20/2017 | SP | TD Bank plans notes linked to 23 Raymond James Quality Yield stocks
|
| 3/1/2017 | IG | New Issue: Johnson & Johnson sells $4.5 billion of senior notes in four tranches
|
| 2/28/2017 | IG | S&P rates Johnson & Johnson notes AAA
|
| 2/28/2017 | IG | Fitch gives AAA to Johnson & Johnson notes
|
| 2/28/2017 | IG | Moody’s rates Johnson & Johnson notes Aaa
|
| 2/28/2017 | IG | Market Commentary: Morning Commentary: High-grade deal pipeline fills; Chevron, Discovery to price; MPLX better
|
| 2/28/2017 | IG | Johnson & Johnson intends to price fixed-rate notes in two tranches
|
| 1/26/2017 | IG | Moody’s affirms Johnson & Johnson on news
|
| 12/29/2016 | SP | New Issue: RBC prices $2 million contingent coupon barrier autocallables on two pharma stocks
|
| 12/13/2016 | SP | RBC plans autocallables with memory coupon linked to pharma stocks
|
| 11/22/2016 | SP | New Issue: Morgan Stanley prices $6.24 million trigger participation notes linked to 45 stocks
|
| 6/2/2016 | GNSP | BNP to sell buffered return enhanced notes on 15 clean energy stocks
|
| 5/11/2016 | IG | S&P rates Johnson & Johnson notes AAA
|
| 5/11/2016 | IG | Fitch gives Johnson & Johnson notes AAA
|
| 5/11/2016 | IG | Moody’s rates Johnson & Johnson notes Aaa
|
| 5/5/2016 | GNSP | BNP plans buffered return enhanced notes on 15 clean energy stocks
|
| 5/5/2016 | GNSP | BNP to sell buffered return enhanced notes on 15 clean energy stocks
|
| 5/2/2016 | SP | RBC to price direct investment notes linked to stable growth basket
|
| 4/4/2016 | GNSP | BNP to sell buffered return enhanced notes on clean energy basket
|
| 4/4/2016 | GNSP | BNP plans buffered return enhanced notes on 15 clean energy stocks
|
| 3/9/2016 | GNSP | Market Commentary: BNP Paribas offers exposure to clean energy with leveraged notes linked to basket of 15 stocks
|
| 3/8/2016 | SP | BNP plans buffered return enhanced notes tied to basket of 15 stocks
|
| 2/29/2016 | IG | Market Commentary: Morning Commentary: Primary action set; Kellogg better; Johnson & Johnson flat; CDX firms
|
| 2/26/2016 | EMHYMUPFPV | Market Commentary: Wells Fargo sells $3.75 billion to end busy week; Johnson & Johnson, Goldman, MUFG tighten
|
| 2/26/2016 | IG | Market Commentary: Wells Fargo prices $3.75 billion to end busy week; Johnson & Johnson, Goldman, MUFG tighten
|
| 2/26/2016 | IG | New Issue: Johnson & Johnson details $7.5 billion sale of notes in seven parts
|
| 2/26/2016 | IG | S&P rates Johnson & Johnson notes AAA
|
| 2/25/2016 | EMHYMUPFPV | Market Commentary: Johnson & Johnson, Union Pacific, GM Financial price deals; MUFG, Goldman Sachs firm
|
| 2/25/2016 | IG | Market Commentary: Primary activity resumes with Johnson & Johnson, Union Pacific deals; MUFG, Goldman Sachs firm
|
| 2/25/2016 | IG | New Issue: Johnson & Johnson sells $7.5 billion of senior notes in seven parts
|
| 2/25/2016 | IG | Moody’s applies Aaa to J&J notes
|
| 2/25/2016 | IG | Fitch rates Johnson & Johnson notes AAA
|
| 2/25/2016 | IG | Johnson & Johnson planning to price offering of senior notes
|
| 2/11/2016 | SP | Morgan Stanley to price buffered return notes linked to 30 stocks
|
| 10/23/2015 | SP | New Issue: RBC prices $2.7 million bullish barrier enhanced notes on five stocks
|
| 10/20/2015 | SP | New Issue: RBC prices $410,000 bullish barrier enhanced notes linked to five stocks
|
| 10/19/2015 | SP | RBC plans 0% bullish barrier enhanced notes on basket of five stocks
|
| 10/15/2015 | SP | RBC plans bullish barrier enhanced return notes on five stocks
|
| 10/7/2015 | SP | New Issue: Credit Suisse prices $526,000 trigger phoenix autocallables linked to Johnson & Johnson
|
| 9/24/2015 | SP | Credit Suisse plans trigger phoenix autocallables linked to Johnson
|
| 9/4/2015 | GNSP | Bank of Montreal plans notes tied to 15 stocks on Ameriprise SRI list
|
| 9/4/2015 | GNSP | Bank of Montreal plans one-year notes linked to Ameriprise SRI stocks
|
| 8/7/2015 | SP | Bank of Montreal plans notes linked to Ameriprise SRI stocks for July
|
| 8/7/2015 | SP | Bank of Montreal plans notes tied to Ameriprise SRI equity focus list
|
| 7/8/2015 | SP | Bank of Montreal plans notes tied to Ameriprise SRI equity focus list
|
| 7/8/2015 | SP | Bank of Montreal to price notes linked to Ameriprise SRI stocks
|
| 6/18/2015 | SP | New Issue: Citigroup prices $4 million contingent coupon autocallables linked to three stocks
|
| 6/15/2015 | SP | Citigroup plans contingent coupon autocallables linked to three stocks
|
| 6/5/2015 | GNSP | Bank of Montreal to price notes on Ameriprise SRI equity focus list
|
| 6/5/2015 | GNSP | Bank of Montreal plans notes tied to Ameriprise SRI equity focus list
|
| 5/29/2015 | SP | New Issue: Morgan Stanley sells $3.82 million contingent income autocallables on two stocks
|
| 5/14/2015 | SP | Morgan Stanley plans contingent income autocallables on two stocks
|
| 4/30/2015 | SP | New Issue: JPMorgan prices $2.81 million autocallable contingent interest notes linked to stocks
|
| 4/17/2015 | SP | JPMorgan plans contingent interest autocallables tied to three stocks
|
| 1/16/2015 | SP | New Issue: Credit Suisse sells $1 million contingent coupon autocallable yield notes on three stocks
|
| 11/19/2014 | IG | New Issue: Johnson & Johnson sells upsized $2 billion of senior notes in five parts
|
| 11/18/2014 | EMHYMUPFPV | Market Commentary: Citigroup, Fluor price; Ares Capital upsizes; AT&T, Verizon notes widen
|
| 11/18/2014 | IG | Market Commentary: Citigroup, Fluor price; Ares Capital upsizes; AT&T, Verizon notes widen
|
| 11/18/2014 | IG | Fitch provides AAA to J&J debt
|
| 11/18/2014 | IG | S&P gives J&J notes AAA
|
| 11/18/2014 | IG | Moody’s applies Aaa to J&J notes
|
| 11/18/2014 | IG | Market Commentary: Morning Commentary: High-grade spreads firm as primary heats up; Gilead, Walgreens improve
|
| 11/18/2014 | IG | Johnson & Johnson planning offering of senior notes
|
| 11/4/2014 | SP | New Issue: Credit Suisse prices $660,000 contingent coupon autocallable yield notes on four stocks
|
| 10/29/2014 | SP | Credit Suisse plans contingent coupon autocallables on four stocks
|
| 9/24/2014 | SP | JPMorgan plans five-year contingent coupon notes linked to 15 stocks
|
| 9/17/2014 | SP | JPMorgan plans five-year contingent coupon notes linked to 15 stocks
|
| 9/11/2014 | SP | JPMorgan plans five-year contingent coupon notes linked to 15 stocks
|
| 4/10/2014 | IG | Market Commentary: Ventas, Worthington Industries price tight; Exxon better; Johnson & Johnson long bonds fall
|
| 2/20/2014 | SP | New Issue: UBS prices $1.55 million trigger phoenix autocallables linked to three stocks
|
| 12/6/2013 | IG | Fitch assigns Johnson & Johnson notes AAA
|
| 12/3/2013 | IG | S&P assigns J&J notes AAA
|
| 12/2/2013 | IG | S&P rates Johnson & Johnson notes AAA
|
| 12/2/2013 | IG | Moody's assigns J&J notes Aaa
|
| 12/2/2013 | IG | Market Commentary: Johnson & Johnson, CVS, Starbucks bring new deals; Starbucks firms in secondary
|
| 12/2/2013 | IG | Johnson & Johnson plans fixed-, floating-rate notes in two tranches
|
| 12/2/2013 | IG | New Issue: Johnson & Johnson sells $3.25 billion of senior notes in six parts
|
| 6/14/2012 | IG | Moody's lifts J&J to stable
|
| 4/25/2012 | IG | Fitch affirms J&J
|
| 1/24/2012 | IG | Moody's: J&J's Aaa unaffected
|
| 11/21/2011 | IG | Moody's rates J&J loan Aaa
|
| 7/13/2011 | CVIG | Moody's affirms Johnson, Microsoft
|
| 5/18/2011 | IG | New Issue: Johnson & Johnson gives terms of $3.75 billion notes in six tranches
|
| 5/17/2011 | IG | S&P rates Johnson notes AAA
|
| 5/17/2011 | IG | Moody's rates Johnson notes Aaa
|
| 5/17/2011 | IG | Fitch rates Johnson notes AAA
|
| 5/17/2011 | IG | Market Commentary: J&J, Aetna, HSBC, Rio Tinto among issuers in frenzied primary; Google's 10-year notes widen
|
| 5/17/2011 | IG | New Issue: Johnson & Johnson sells $3.75 billion of bonds in upsized six tranches
|
| 4/29/2011 | IG | Fitch puts Johnson on watch
|
| 4/27/2011 | IG | Moody's: Johnson to negative
|
| 2/28/2011 | IG | Johnson & Johnson files automatic shelf registration covering debt
|
| 10/18/2010 | IG | Market Commentary: Wal-Mart sets record-low coupon; CSX sells two tranches; Wal-Mart debt firms; CDS costs fall
|
| 8/19/2010 | IG | Market Commentary: Baker Hughes, Rowan, Caterpillar sell bonds; low coupon hunt continues; spreads remain firm
|
| 8/16/2010 | IG | Fitch rates J&J notes AAA
|
| 8/13/2010 | IG | Market Commentary: Investment-grade activity to pick up at mid-week, J&J oversubscribed; secondary quiet
|
| 8/12/2010 | IG | S&P rates Johnson & Johnson notes AAA
|
| 8/12/2010 | IG | Moody's rates J&J bond Aaa
|
| 8/12/2010 | IG | Market Commentary: Johnson & Johnson nets record-low coupons; Detroit Edison upsizes; new debt firms in secondary
|
| 8/12/2010 | IG | New Issue: Johnson & Johnson sells $1.1 billion notes in 10-, 30-year tranches
|
| 3/22/2010 | SP | New Issue: Barclays prices $5.5 million 1% five-year notes linked to Johnson & Johnson
|
| 2/10/2010 | BKBWHY | Elan reduces net debt to $650 million, enhances liquidity in 2009
|
| 10/8/2009 | IG | Moody's rates new J&J loan Aaa
|
| 9/14/2009 | SS | Elan cures breach; Johnson & Johnson drops price for interest in company
|
| 8/25/2009 | IG | Market Commentary: Duke Energy, Spectra Energy, Procter & Gamble bring quick bond sales; AmEx tighter in trading
|
| 7/10/2009 | SS | Johnson & Johnson completes acquisition of Cougar Biotechnology
|
| 7/7/2009 | SS | Gamco sells 1.11 million recently acquired Cougar Biotechnology shares
|
| 7/6/2009 | SS | Johnson & Johnson's follow-up tender offer for Cougar ends Thursday
|
| 7/2/2009 | SS | Johnson & Johnson to buy Elan's interest in Alzheimer's program
|
| 6/30/2009 | SS | Gamco buys stake in Cougar Biotechnology ahead of merger with J&J
|
| 6/24/2009 | IG | Fitch affirms Johnson & Johnson
|
| 6/17/2009 | SS | Johnson & Johnson, Cougar Biotechnology merger closer to completion
|
| 6/16/2009 | SS | Market Commentary: Analyst: Sell Data Domain equity now; Merck, Schering meetings set; GM inks deal to sell Saab
|
| 6/5/2009 | SS | Johnson & Johnson begins tender offer for Cougar Biotechnology
|
| 6/5/2009 | SS | Market Commentary: Icahn burrows into Amylin, Biogen; NRG sets date for Exelon clash; Cougar buyout on track
|
| 5/28/2009 | SS | Johnson & Johnson tries to cancel distribution agreement with Schering
|
| 5/27/2009 | SS | Market Commentary: Amylin gives up two board seats; AOL spinoff buzz increases; Cougar lacks counter bids
|
| 5/22/2009 | SS | Market Commentary: Target blocks meeting web cast; Cougar takeover needs minimal review; Logility set for buyout
|
| 5/21/2009 | SS | Cougar to be bought by Johnson & Johnson for $970 million
|
| 5/1/2009 | IG | Market Commentary: Coca-Cola Enterprises, Rockwell Collins, BP Capital sell notes; overwhelming demand for deals
|
| 4/23/2009 | SS | Market Commentary: Centennial buyout could let AT&T walk; Emulex auction expected; major pharma mergers predicted
|
| 3/18/2009 | SS | Market Commentary: Sun Microsystems stock surges; NRG takes legal action; J&J might challenge Schering-Plough merger
|
| 3/11/2009 | SS | Market Commentary: Johnson & Johnson a thorn in Merck deal; Nobel Learning gets cheap bid; sale likely for Charlotte Russe
|
| 3/10/2009 | SS | Market Commentary: Merck merger hinges on regulatory OKs; Rohm gains from Dow's tardiness; United Tech on the hunt
|
| 3/9/2009 | IG | Market Commentary: GE Capital, Bank of America, Medtronic, PG&E sell notes; spread widen
|
| 1/28/2009 | IG | Market Commentary: Bank of America adds to FDIC-backed notes, Fed, earnings take toll on issuance; Washington Post, Entergy gain
|
| 1/26/2009 | SP | New Issue: Citigroup prices $24.34 million 8% ELKS linked to Johnson & Johnson
|
| 1/23/2009 | SS | Mentor investors tender 93.9% of shares in offer by Johnson & Johnson; merger closes
|
| 1/20/2009 | SS | Johnson & Johnson begins subsequent offer for Mentor shares
|
| 1/16/2009 | SS | Market Commentary: Risks weigh on Terra takeover; Aladdin deal should clear regulatory reviews; Mentor bid expires
|
| 1/15/2009 | SS | Johnson & Johnson receives all required clearances in proposed acquisition of Mentor
|
| 1/15/2009 | SS | Market Commentary: Johnson & Johnson offer for Mentor expires Friday; International Shipholding falls on loss of suitor
|
| 1/6/2009 | SS | Johnson & Johnson extends tender offer for Mentor
|
| 1/6/2009 | SS | Market Commentary: Endo buyout likely to close; Rohm & Haas stock falls below Dow bid; Johnson & Johnson extends offer
|
| 1/2/2009 | SS | Market Commentary: Zell homes in on Starwood Hotels; Dynegy quits joint venture
|
| 12/31/2008 | IG | Outlook 2009: New year brings hope investment-grade secondary will revert to traditional levels
|
| 12/31/2008 | SP | New Issue: ABN Amro prices $0.55 million 10% reverse convertibles linked to Johnson & Johnson
|
| 12/31/2008 | SS | Omrix now part of Johnson & Johnson
|
| 12/31/2008 | SS | Outlook 2009: Deal volume predicted to drop 25%; new year a buyer's market for companies with cash
|
| 12/24/2008 | SS | Market Commentary: Johnson & Johnson tender offer for Omrix expires Friday; Emageon buyout lacks financing
|
| 12/23/2008 | SP | Citigroup to price 8%-10% ELKS linked to Johnson & Johnson
|
| 12/22/2008 | SS | Market Commentary: Johnson & Johnson, King Pharma buyouts considered done deals; InfoGroup founder explores sale
|
| 12/19/2008 | SS | Johnson & Johnson extends tender offer for Omrix
|
| 12/16/2008 | SP | New Issue: ABN Amro prices $0.3 million 10% reverse convertibles linked to Johnson & Johnson
|
| 12/12/2008 | SS | Johnson & Johnson begins tender offer for Mentor
|
| 12/12/2008 | SS | Market Commentary: PNC, NatCity await Fed blessing; tender for Mentor opens; Rodman & Renshaw sticks to takeover target
|
| 12/11/2008 | SS | Johnson & Johnson, Omrix merger granted approval in Israel; tender offer ends Dec. 23
|
| 12/9/2008 | SP | ABN Amro to price 10% reverse exchangeables linked to Johnson & Johnson
|
| 12/9/2008 | SP | ABN Amro to price 10% reverse exchangeables linked to Johnson & Johnson
|
| 12/3/2008 | IG | Market Commentary: Wells Fargo prices FDIC-backed deal, Potomac Electric, Enterprise Products issue; Caterpillar tightens, Nexen eases
|
| 12/1/2008 | SS | Johnson & Johnson to acquire Mentor for $1.07 billion
|
| 12/1/2008 | SS | Market Commentary: J&J offer sends Mentor up 89.35%; Sprint Nextel, Clearwire close deal; BCE shares set new low
|
| 11/26/2008 | SP | New Issue: ABN Amro prices $0.3 million 10.75% reverse convertibles linked to Johnson & Johnson
|
| 11/25/2008 | SS | Johnson & Johnson begins tender offer for Omrix
|
| 11/24/2008 | SS | Market Commentary: Citi rescue sparks rally; King takes Alpharma for $37 a share; J&J to buy Omrix; LandAmerica sinks
|
| 11/24/2008 | SS | Johnson & Johnson to buy Omrix for $438 million
|
| 11/12/2008 | SP | ABN Amro plans 10.75% Knock-in Reverse Exchangeables linked to Johnson & Johnson
|
| 10/29/2008 | SP | New Issue: UBS prices $468,809 11% yield optimization notes linked to Johnson & Johnson
|
| 10/17/2008 | SP | UBS to price 6.5%-9% yield optimization notes linked to Johnson & Johnson
|
| 10/14/2008 | IG | Market Commentary: Issuers wait for price discovery; high yields also deter; Morgan Stanley, Johnson & Johnson tighten
|
| 10/6/2008 | IG | Moody's gives Johnson & Johnson loan Aaa
|
| 7/2/2008 | IG | Fitch affirms Johnson & Johnson
|
| 6/30/2008 | IG | Market Commentary: June ends with nearly $62 billion issuance; industrial issuers expected to dominate first part of July
|
| 6/26/2008 | IG | Market Commentary: Bond market freezes on stock market slide, analyst reports, oil; lull seen running into July
|
| 6/25/2008 | IG | Market Commentary: GS Caltex prices; Zions Bancorp, ANZ plan upcoming issues
|
| 6/24/2008 | IG | Market Commentary: Rio Tinto, Rockies Express, Prudential price ahead of Fed; little action expected for rest of week
|
| 6/19/2008 | IG | S&P rates J&J notes AAA
|
| 6/19/2008 | IG | Fitch rates J&J notes AAA
|
| 6/18/2008 | IG | New Issue: Johnson & Johnson prices $1.6 billion notes in 10-, 30-year tranches
|
| 6/18/2008 | IG | Moody's rates J&J notes Aaa
|
| 6/18/2008 | IG | Market Commentary: Johnson & Johnson, MetLife price issues; calendar for balance of week seen slow
|
| 5/6/2008 | SP | New Issue: Bank of America prices $58 million 10% notes exchangeable for Johnson & Johnson
|
| 3/3/2008 | SP | New Issue: JPMorgan prices $1.05 million 10% notes linked to Procter & Gamble, Johnson & Johnson
|
| 12/14/2007 | IG | Moody's rates Johnson & Johnson loans Aaa
|
| 12/10/2007 | SP | New Issue: ABN Amro prices $2 million 7.45% knock-in notes linked to Johnson & Johnson
|
| 10/30/2007 | IG | S&P rates Johnson & Johnson notes AAA
|
| 10/30/2007 | IG | Moody's gives Johnson & Johnson notes Aaa
|
| 10/30/2007 | IG | Fitch gives Johnson & Johnson notes AAA
|
| 8/17/2007 | IG | Market Commentary: Week ends on high note as Wal-Mart prices $2.75 billion new issue
|
| 8/14/2007 | IG | Market Commentary: New deals keep rolling in as investment-grade market remains stable; New Johnson & Johnson tighter
|
| 8/13/2007 | IG | Moody's rates Johnson & Johnson notes Aaa
|
| 8/13/2007 | IG | Fitch assigns Johnson & Johnson notes AAA
|
| 8/13/2007 | IG | Market Commentary: Investment grade takes on better tone after negative week; Johnson & Johnson prices $2.6 billion
|
| 8/13/2007 | IG | New issue: Johnson & Johnson prices $2.6 billion deal in three tranches
|
| 8/13/2007 | IG | S&P gives Johnson & Johnson notes AAA
|
| 1/31/2007 | SS | Conor Medsystems' merger with Johnson & Johnson, Cordis approved
|
| 1/9/2007 | SS | Johnson & Johnson acquisition of Conor Medsystems cleared by FTC
|
| 11/13/2006 | BTCV | Johnson & Johnson files automatic shelf registration
|
| 10/17/2006 | BT | Johnson & Johnson rated at outperform by RBC
|
| 10/17/2006 | BT | Market Commentary: Icos gains 16% on Lilly buyout; Millennium forfeits AnorMED; InterMune rises 25%; OSI better
|
| 9/26/2006 | BT | Cordis: FDA approves stent system for carotid artery disease
|
| 9/19/2006 | BT | Johnson & Johnson: Paliperidone aids sleep onset, duration in schizophrenia
|
| 9/6/2006 | BT | Cordis gets European approval for stent to treat arterial disease in the leg
|
| 9/6/2006 | BT | Cordis: Cypher stent provides sustained benefits in coronary artery disease patients
|
| 9/5/2006 | BT | Cordis' Cypher stent slightly more effective than Taxus stent, data shows
|
| 8/30/2006 | BT | S&P: Johnson & Johnson unchanged
|
| 8/22/2006 | BT | Johnson & Johnson company receives FDA approval for automated ablation system for heart condition
|
| 8/16/2006 | BT | RBC Capital Markets orthopedic report: hip market up at $1.1 billion, growth rates slow
|
| 8/14/2006 | BT | Centocor's Remicade expanded for inhibiting joint damage, improving physical function
|
| 8/7/2006 | BT | Epigenomics, J&J Pharmaceutical form research, development agreement
|
| 7/27/2006 | BT | Cordis' Cypher stent more cost-effective than Taxus stent, study says
|
| 7/21/2006 | BT | Merrill maintains Amgen at neutral
|
| 7/21/2006 | BT | Johnson & Johnson Pharmaceutical Research says FDA's paliperidone meeting cancelled
|
| 7/19/2006 | BT | RBC rates Johnson & Johnson at outperform
|
| 7/19/2006 | BT | Johnson & Johnson kept at market perform by JMP
|
| 7/18/2006 | BT | Johnson & Johnson reports record second-quarter sales of $13.4 billion
|
| 7/12/2006 | BT | Johnson & Johnson once-daily paliperidone maintains schizophrenia stability in phase 3 study
|
| 7/6/2006 | BT | MGI Pharma, Cilag form license agreement to develop Dacogen for Injection
|
| 7/3/2006 | BT | Fitch affirms Johnson & Johnson
|
| 6/30/2006 | BT | Vertex forms collaboration with Johnson & Johnson companies to promote VX-950 for hepatitis C
|
| 6/27/2006 | BT | Moody's affirms Johnson & Johnson
|
| 6/27/2006 | BT | Johnson & Johnson at outperform by RBC
|
| 6/26/2006 | BT | Market Commentary: Vasogen plunges 74%; Anadys falls 45%; Nastech, Amylin gain on pact; Neurocrine finds buyers
|
| 6/26/2006 | BT | Johnson & Johnson to acquire Pfizer Consumer Healthcare for $16.6 billion in cash
|
| 6/26/2006 | BT | S&P: Johnson & Johnson unaffected
|
| 6/22/2006 | BT | Cordis' CypherSelect Plus stent approved in Europe
|
| 6/21/2006 | BT | Johnson & Johnson at peer perform by Bear Stearns
|
| 6/15/2006 | BT | Cordis to appeal court ruling upholding Boston Scientific stent patent
|
| 6/12/2006 | BT | Boston Scientific data shows 'excellent' outcomes for Taxus stent in diabetics
|
| 6/1/2006 | BT | Johnson & Johnson, PharmaMar seek U.S., European approval for trabectedin for soft tissue sarcoma
|
| 5/24/2006 | BT | Centocor compares ulcerative colitis remission to employment, disability compensation
|
| 5/23/2006 | BT | Johnson& Johnson's paliperidone tablets show efficacy in treating schizophrenia patients
|
| 5/19/2006 | BT | FDA approves Centocor's Remicade for children with Crohn's disease
|
| 5/16/2006 | BT | Cordis study suggests drug-eluting stent, size important reblockage predictors
|
| 5/15/2006 | BT | Cordis patient registry to evaluate long-term safety, efficacy of drug-eluting coronary stents
|
| 5/11/2006 | BT | Court upholds decisions in Boston Scientific, Johnson & Johnson patent case
|
| 5/11/2006 | BT | Cordis files PMA for Cypher coronary stent
|
| 4/28/2006 | BT | Johnson & Johnson Pharmaceutical, Ortho-McNeil developing novel analgesic for acute pain
|
| 4/19/2006 | BT | JMP maintains J&J at market perform
|
| 4/18/2006 | BT | Johnson & Johnson says 1Q06 earnings up 16% on $12.992 billion of sales
|
| 3/23/2006 | BT | Medtronic wins stent patent arbitration with Cordis
|
| 3/15/2006 | BT | Cordis says stem cells a benefit to heart disease patients; FDA clears NOGA
|
| 3/13/2006 | BT | Studies suggest Cypher stent outperforms Taxus in some patients
|
| 3/6/2006 | BT | Millennium, Johnson & Johnson Pharmaceutical start Velcade trial for lung cancer
|
| 2/27/2006 | BT | Analyst updates cardiology market from East Coast session
|
| 2/8/2006 | BTCV | New Issue: Wachovia sells $2 million exchangeables linked to Johnson & Johnson at 2%, up 14.75%
|
| 2/7/2006 | BT | Arena, Ortho-McNeil initiate phase 1 trial for type 2 diabetes oral drug candidate
|
| 2/2/2006 | BT | Johnson & Johnson says Cypher stent outperforms Taxus in small vessel trial
|
| 2/2/2006 | BTCV | Wachovia to price 2% notes exchangeable for Johnson & Johnson
|
| 1/30/2006 | BT | Johnson & Johnson's Ionsys analgesic system approved by European Commission
|
| 1/30/2006 | BT | E.U. committee recommends approval of Remicade for active ulcerative colitis
|
| 1/23/2006 | BT | Johnson & Johnson study confirms Regranex gel effective treatment of foot ulcers
|
| 1/13/2006 | BT | Johnson & Johnson ups offer for Guidant to $71 a share
|
| 1/12/2006 | BT | Moody's affirms Johnson & Johnson
|
| 1/11/2006 | BT | Johnson & Johnson raises bid to $23.2 billion to acquire Guidant, says both boards agree on deal
|
| 12/19/2005 | BT | Johnson & Johnson unit gets FDA approval for catheter component of Sterotaxis system
|
| 12/16/2005 | BT | Johnson & Johnson to acquire insulin-pump maker Animas for $518 million
|
| 12/16/2005 | BT | JMP reiterates market perform for J&J
|
| 12/14/2005 | BT | Johnson & Johnson's paliperidone ER improves schizophrenia symptoms, studies say
|
| 12/12/2005 | BT | Millennium, Johnson & Johnson plan additional studies in response to Velcade results
|
| 12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
| 11/16/2005 | BT | Moody's affirms Johnson & Johnson
|
| 11/16/2005 | BT | J&J maintained by JMP at market perform
|
| 11/15/2005 | BT | S&P affirms Johnson & Johnson
|
| 11/7/2005 | BT | Market Commentary: Solid earnings fuel ViroPharma stock; Guidant sues Johnson & Johnson over proposed merger
|
| 10/19/2005 | BT | JMP raises estimates of J&J
|
| 6/30/2005 | CV | New Issue: Citigroup prices $20 million notes exchangeable for Johnson & Johnson at 1%, up 16.384%
|
| 12/7/2004 | CV | Market Commentary: CMS new deal bid at issue; Dress Barn bid up 3.5 points; Seacor launches overnighter
|
| 10/2/2003 | CV | Market Commentary: Providian gains sharply amidst big volume on talk about Wells Fargo takeover; buyers aplenty
|
| 7/22/2003 | CV | Market Commentary: Buyers tiptoeing back into market as premiums contract; Wells Fargo rekindles dividend fears
|
| 6/11/2003 | CV | Market Commentary: Xerox emerges as a mandatory; Mirant in freefall; Tyco gains on unit sale talk; airlines fly high
|
| 3/10/2003 | CV | Deutsche urges caution on 0% convertibles vulnerable to cash call after Costco announcement
|
| 3/5/2003 | CV | Market Commentary: Watson trades up out of gate, Provident plunges, call scare ripples throughout market
|
| 7/22/2002 | CV | Market Commentary: Players remain on the sidelines as stocks continue sharp slide
|
| 2/13/2002 | CV | Market Commentary: Convertibles marked up but focus remains on decliners
|
| 1/22/2002 | CV | Market Commentary: Convertibles lower on worries about tech valuations, Tyco rebounds
|
| 1/10/2002 | CV | Market Commentary: Convertibles flat with hints of a retreat to quality
|
| 12/21/2001 | CV | Market Commentary: Convertibles higher on rise in confidence, Nortel, Calpine gains
|
| 10/24/2001 | CV | UBS convertible analysts: stocks may not recover soon, so play defensive
|
